Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Steris ( (STE) ) has issued an update.
On May 1, 2026, long-serving director Richard C. Breeden informed STERIS that he would not stand for reelection at the 2026 annual meeting, ending an 18-year tenure without any disagreement over company operations or policies. The board acknowledged his retirement and, on May 5, 2026, expanded its size from nine to ten members and appointed bioMérieux chief executive Pierre Boulud as a director.
Boulud, an experienced healthcare and biotechnology executive with prior leadership roles at bioMérieux and Ipsen and a background in strategic consulting, brings substantial global commercial and operational expertise to the STERIS board. His appointment, announced publicly on May 7, 2026, signals a continued emphasis on international growth and strategic execution in infection prevention and related healthcare markets, while aligning new board compensation to equity-based incentives through restricted stock units.
The most recent analyst rating on (STE) stock is a Buy with a $300.00 price target. To see the full list of analyst forecasts on Steris stock, see the STE Stock Forecast page.
Spark’s Take on STE Stock
According to Spark, TipRanks’ AI Analyst, STE is a Neutral.
The score is primarily driven by solid fundamentals (improving profitability and strong cash generation) and a constructive earnings update with maintained FY2026 guidance. These positives are tempered by weak near-term technicals (trading below major moving averages with negative momentum) and a relatively expensive valuation (P/E ~36.5 with ~1% yield), plus tariff-driven margin pressure highlighted on the call.
To see Spark’s full report on STE stock, click here.
More about Steris
STERIS plc is a leading global provider of products and services that support patient care with a focus on infection prevention across healthcare and life sciences markets. The company offers innovative solutions designed to help hospitals, laboratories and related customers create safer clinical and research environments worldwide.
Average Trading Volume: 800,922
Technical Sentiment Signal: Sell
Current Market Cap: $21.03B
See more insights into STE stock on TipRanks’ Stock Analysis page.